Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
Yueyue Liu, Qian Zhang, Chao Lu, Wei Hu Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, 230601, People’s Republic of ChinaCorrespondence: Chao Lu; Wei HuDepartment of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei,...
Saved in:
Main Authors: | Liu Y (Author), Zhang Q (Author), Lu C (Author), Hu W (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential effects of ketoconazole, fluconazole, and itraconazole on the pharmacokinetics of pyrotinib in vitro and in vivo
by: Li Wang, et al.
Published: (2022) -
Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
by: Miao Zhang, et al.
Published: (2022) -
A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients
by: Yunfang Zhu, et al.
Published: (2024) -
Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
by: Wang C, et al.
Published: (2024) -
Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023)